Do I Have Alpha-1?
Your family history and current symptoms may provide clues
CSL Behring has designed an interactive tool that you can use to assess your chances
for having Alpha-1. It asks some important questions about your family history,
your medical history, and the symptoms you're experiencing, then generates an
evaluation based on your responses. Be sure to share your answers with your doctor
to help him or her make the best decisions regarding your overall care.
Take the Alpha-1 Questionnaire and learn more
This brief questionnaire can help you understand your chances for having Alpha-1.
Be aware that your answers are completely confidential – there is no sign-in
required. The questionnaire takes less than 2 minutes to complete but can provide
valuable insights regarding your health.
Let's Get Started
Questionnaire Results
Your score:
- LOW
1-9
- MEDIUM
10-22
- HIGH
23-30
You have a LOW score. Continue
to follow your doctor's instructions regarding any symptoms you may be experiencing.
If your symptoms linger or worsen, you may want to consider getting tested for Alpha-1.
Print your assessment result and keep it on hand for future reference.
You have a MEDIUM score. Talk with your doctor about this
evaluation to discuss the need for testing for Alpha-1. Print this results page
and bring it with you to your doctor's office for discussion.
Remember:
Not all genetically predisposed individuals will develop clinically significant
symptoms. Your doctor can conduct tests to determine if you have Alpha-1.
You have a HIGH score. Talk with your doctor about this assessment
to discuss the need for testing yourself and your family members for Alpha-1. Remember
to print your assessment result and bring it with you to your doctor's office.
Important Safety Information
Alpha1-Proteinase Inhibitor (Human), Zemaira® is indicated for chronic augmentation and maintenance therapy for adults with alpha1-proteinase inhibitor (A1-PI) deficiency and emphysema. Clinical data demonstrating the long-term effects of chronic augmentation therapy with Zemaira are not available.
Zemaira may not be appropriate for the following adult individuals as they may experience severe reactions, including anaphylaxis: individuals with a known hypersensitivity and/or history of anaphylaxis or severe systemic reaction to A1-PI products or their components, and individuals with selective IgA deficiencies who have known antibodies against IgA.
In clinical studies, the following treatment-related adverse reactions were reported in 1% of subjects: asthenia (fatigue), injection-site pain, dizziness, headache, paresthesia (tingling), and pruritus (itching).
Zemaira is derived from human plasma. The risk of transmission of infectious agents, including viruses and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent, cannot be completely eliminated.
Please see full prescribing information.
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.